Intra-Cellular Therapies Submits Supplemental New Drug Application to FDA for CAPLYTA for the Treatment of Major Depressive Disorder as Adjunctive Therapy
| FRBRX Fund | USD 147.44 1.08 0.74% |
Slightly above 53% of Franklin Biotechnology's investor base is interested to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are impartial at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTAs robust antidepressant efficacy and favorable safety and tolerability profileCAPLYTA, if approved as an adjunctive therapy in MDD, would be indicated for the treatment of three different major psychiatry indications affecting over 30 million adult patients in the US BEDMINSTER, N.J., Dec. 03, 2024 -- Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused o
Read at finance.yahoo.com
 |
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Five Year Return
Five Year Return Comparative Analysis
Franklin Biotechnology is currently under evaluation in five year return among similar funds. Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| TEBIX | Franklin Mutual | 0.53 |
| ||
| TEDSX | Franklin Mutual | 0.54 |
| ||
| TEDRX | Franklin Mutual | 0.55 |
| ||
| TEGBX | Templeton Global | 0.59 |
| ||
| TEGRX | Templeton Growth | 0.64 |
| ||
| TEFRX | Templeton Foreign | 0.64 |
| ||
| TEDIX | Franklin Mutual | 0.64 |
| ||
| TEMFX | Templeton Foreign | 0.75 |
| ||
| TEDMX | Templeton Developing | 0.91 |
| ||
| TEFTX | Templeton Foreign | 1.11 |
|
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |